Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 0.51 |
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.51 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.51 |
| ▸ | FABP3 | P05413 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8162887 | 0.85 | SOAT2 (0.46) | SOAT2MYCSOAT1MAP2K3FABP3 | |
| SCHEMBL7620745 | 0.78 | FABP3 (0.39) | SOAT2MYCSOAT1MAP2K3FABP3 | |
| SCHEMBL5475540 | 0.77 | SOAT2 (0.46) | SOAT2MYCSOAT1MAP2K3FABP3 | |
| SCHEMBL5458696 | 0.75 | SOAT2 (0.44) | SOAT2MYCSOAT1MAP2K3FABP3 | |
| SCHEMBL8703488 | 0.75 | SOAT2 (0.44) | SOAT2MYCSOAT1MAP2K3FABP3 | |
| SCHEMBL7565653 | 0.74 | SOAT2 (0.63) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL8703489 | 0.70 | FABP3 (0.40) | SOAT2MYCSOAT1MAP2K3FABP3 | |
| SCHEMBL28412857 | 0.70 | SOAT2 (0.68) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL8618922 | 0.70 | SOAT2 (0.58) | SOAT2MYCSOAT1MAP2K3FABP3 | |
| SCHEMBL5456119 | 0.69 | SOAT2 (0.67) | SOAT2MYCSOAT1MAP2K3FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0858336-B1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER LAMBERT CO (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060069163-A1 | Method for treating Alzheimer's disease | PFIZER INC | 2006-03-30 | — | — | US | claimed |
| US-6143755-A | DRUGS FOR RESTORATION OF ENDOGENOUS VASCULAR ACTIVITIES AS ANTICOAGULANTS AND VASODILATION | WARNER-LAMBERT COMPANY (US) | 2000-11-07 | — | — | US | claimed |
| US-6124309-A | ADMINISTERING ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITOR AND HYDROXY-3-METHYLGLUTARYL/3-/ COENZYME A REDUCTASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | claimed |
| US-6093719-A | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACYL-COA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR; FOR PATIENTS WITH OR AT RISK OF DEVELOPING ISCHEMIC SYNDROMES | WARNER-LAMBERT COMPANY (US) | 2000-07-25 | — | — | US | claimed |
| EP-0858336-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1998-08-19 | — | — | EP | claimed |
| WO-1997016184-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1997-05-09 | — | — | WO | claimed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS INC. | 2018-12-06 | — | — | US | disclosed |
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-6093719-A | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACYL-COA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR; FOR PATIENTS WITH OR AT RISK OF DEVELOPING ISCHEMIC SYNDROMES | WARNER-LAMBERT COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| US-6011052-A | Pyrazolone derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0927167-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| EP-0858336-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998006703-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1997016184-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | DNPEP, FOLH1, CTSL | SOAT2 4687/4885MYC 940/4885SOAT1 4563/4885 |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | SOAT2 533/4885MYC 3688/4885SOAT1 384/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | SOAT2 426/4885MYC 3749/4885SOAT1 463/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | SOAT2 432/4885MYC 3751/4885SOAT1 462/4885 |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | SOAT2 533/4885MYC 3688/4885SOAT1 384/4885 |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | SOAT2 533/4885MYC 3688/4885SOAT1 384/4885 |
| US-20060069163-A1 | Method for treating Alzheimer's disease | APOB, HMGCR, PSEN2 | SOAT2 51/4885MYC 4734/4885SOAT1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.